Equillium Q2 net loss $14.1M (-$0.41/sh); cash $57.6M; clinical pipeline on track

Equillium, Inc.

2022-Q2 EPS reported -$1.56

Net loss $14.1M, or $(0.41) per share, vs $9.2M ($0.31) in Q2 2021; R&D spend $9.5M.
Cash, cash equivalents and short-term investments $57.6M as of June 30, 2022.
Phase 3 EQUATOR study of itolizumab in aGVHD continues enrollment; interim data from lupus nephritis study expected mid-2022.
Phase 2 study of EQ101 in alopecia areata and Phase 1 study of EQ102 in celiac disease expected to initiate 2H 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.